国际药物开发与研究杂志

  • 国际标准期刊号: 0975-9344
  • 期刊 h 指数: 44
  • 期刊引用分数: 59.93
  • 期刊影响因子: 48.80
索引于
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 引用因子
  • 西马戈
  • 研究期刊索引目录 (DRJI)
  • OCLC-WorldCat
  • 普布隆斯
  • 米亚尔
  • 大学教育资助委员会
  • 欧洲酒吧
  • 谷歌学术
  • 夏尔巴罗密欧
  • 秘密搜索引擎实验室
  • 研究之门
分享此页面

抽象的

Critical Issues of Pharmaceutical Industry: A Case Study of Recent Advance in the Chemical Synthesis of Tamiflu

Wang-Kin Chiu and Yui Yip Lau

Primary manufacturing is one of the key components in a standard pharmaceutical supply chain. The primary manufacturing site is responsible for the synthesis of the active ingredient of a drug. In the manufacture or design of new synthetic routes of a drug, the logistics cost, availability of starting materials, number of steps and overall yield are critical factors to be taken into account. In view of the importance of oseltamivir phosphate (Tamiflu) in treatment of influenza, related issues and development in pharmaceutical industry should be addressed and updated. In this paper, we will (1) highlight the concepts of Supply Chain Management (SCM) in pharmaceutical industry; (2) describe the recent advance in the synthetic chemistry of Tamiflu, focusing on the new approaches based on inexpensive starting materials. This paper should be of interest to health care study and is expected to provide insights for the drug and supply chain management industry.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证